Atomo (ASX:AT1) share price rockets 10% on new agreement

The Atomo Diagnostics Ltd (ASX: AT1) share price has surged up after a deal was announced to distribute its COVID-19 test kit in India.

| More on:
Young girl wearing a suit and tie with rocket wings looks to the sky representing the highest traded stocks today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Atomo Diagnostics Ltd (ASX: AT1) share price is up after a deal was announced to distribute its COVID-19 test kit in India. The news has sent the Atomo share price rocketing 10% higher to 38 cents at the time of writing.

What does Atomo do?

Atomo Diagnostics is an Australian medical device company that supplies rapid diagnostics tests (RDTs) and devices to the global diagnostics market. Atomo’s devices are intended to simplify testing procedures and usability for professional and untrained users.

The company has supply agreements in place for tests targeting a range of infectious diseases. These include HIV, COVID-19, and viral vs bacterial differentiation.

New sales agreement

Atomo announced a deal with DIVOC Laboratories, an Indian specialist diagnostic company, to launch its AtomoRapid COVID-19 antibody test in India.

Under the agreement, Atomo will provide 77,000 antibody test kits upon DIVOC obtaining product registration approval for professional use. DIVOC is expected to receive approval in Q2 FY21.

DIVOC will distribute the test kits on a non-exclusive basis to government, corporate, and India’s established home-visit network.

The agreement will be terminated should DIVOC fail to order one million units in the 12 months following regulatory approval. In return, Atomo will receive a fixed transfer price per unit and a percentage of revenues on final product sales.

The non-exclusive sale of its COVID-19 rapid test in India is a further expansion of its agreement with NG Biotech.

Atomo co-founder and managing director John Kelly was pleased with Atomo’s global reach. He said:

We are delighted to be able to offer our antibody rapid test in another large international market. Rapid testing forms a significant pillar of India’s response to managing the COVID-19 pandemic with the numbers of daily rapid tests increasing significantly in recent months.

Our Indian partner is a high-quality provider of diagnostic services, being one of the few laboratories in India that has been able to secure NABL accreditation. We are confident of their ability to roll out the AtomoRapid COVID-19 antibody testing across a number of high value channels in India in the coming months.

Is the Atomo share price good value?

I think Atomo has seized an opportunity that could expand its revenue significantly in the coming months. India has a high ranking for daily COVID-19 infections, hitting more than 90,000 cases in a day this month, and 5.65 million cases in total.

The new agreement is another milestone for the company which listed on the ASX in April this year. At a market capitalisation of $213 million, the Atomo share price has moved little since its Q4 update in June. But that could change in future depending on the success of its agreements.

I would encourgae investors to add Atomo to their watchlist and monitor its ongoing developments.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Top ten gold trophy.
Share Market News

Here are the top 10 ASX 200 shares today

These ASX 200 shares ended the week on a high.

Read more »

a shiba inu dog looks happily at eh camera with his tongue out while his owner hods him on his chest as he sleeps on a hammock.

Here’s why the Dogecoin price has had such a great week

Economic data out of the United States and a surprise announcement by BlackRock offered some healthy tailwinds to cryptos over…

Read more »

A pair of legs can bee seen on the floor buried under a pile of paperwork, indicating a high volume day
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Friday

Our most traded ASX 200 share today has lost more than 10%. Ouch.

Read more »

A futuristic view of electric vehicle technology with speeding bright light trails indicating power.
Resources Shares

New records and looming deficits. Why ASX lithium stocks are in the spotlight

Demand for lithium is booming alongside rocketing growth in EV production, sending the price of the battery critical metal up…

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Share Market News

Is the Telstra share price a buy after the telco’s FY22 results?

Is the Telstra share price good value now?

Read more »

A male ASX 200 broker wearing a blue shirt and black tie holds one hand to his chin with the other arm crossed across his body as he watches stock prices on a digital screen while deep in thought
Share Market News

5 things to watch on the ASX 200 on Friday

Here's what to expect on the ASX 200 on Friday...

Read more »

Blue light arrows pointing up, indicating a strong rising share price
Share Market News

Here are the top 10 ASX 200 shares today

These ASX 200 shares bested the rest on Thursday.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Share Market News

Here are the 3 most heavily traded ASX 200 shares on Thursday

Our most traded ASX 200 share of the day was at one stage up 19%...

Read more »